Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

Manuel de la Torre-Aláez,1 Ana Matilla,2,3 Maria Varela,4 Mercedes Inarraiaegui,5,6 Maria Reig,3,6 Jose Luis Lledó,7 Juan Ignacio Arenas,8 Sara Lorente,9 Milagros Testillano,10 Laura Márquez,2 Leonardo Da Fonseca,6 Josepmaria Argemi,3,5 Carlos Gómez-Martín,11 Macarena Rodríguez-Fraile,1,12 Jose I Bilbao,13 Bruno Sangro3,5

ABSTRACT

Purpose To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor in patients with unresectable hepatocellular carcinoma (uHCC) and liver-only disease ineligible for chemoembolization.

Patients and methods NASIR-HCC is a single-arm, multicenter, open-label, phase 2 trial that recruited from 2017 to 2019 patients who were naïve to immunotherapy and had tumors in the BCLC B2 substage (single or multiple tumors beyond the up-to-7 rule), or unilobar tumors with segmental or lobar portal vein invasion (PVI); no extrahepatic spread; and preserved liver function. Patients received SIRT followed 3 weeks later by nivolumab (240 mg every 2 weeks) for up to 24 doses or until disease progression or unacceptable toxicity. Safety was the primary endpoint. Secondary objectives included objective response rate (ORR), time to progression (TTP), and overall survival (OS).

Results 42 patients received SIRT (31 BCLC-B2, 11 with PVI) and were followed for a median of 22.2 months. 27 patients discontinued and 1 never received nivolumab. 41 patients had any-grade adverse events (AE) and 21 had serious AEs (SAE). Treatment-related AEs and SAEs grade 3–4 occurred in 8 and 5 patients, respectively. Using RECIST 1.1 criteria, ORR reported by investigators was 41.5% (95% CI 26.3% to 57.9%). Four patients were downstaged to partial hepatectomy. Median TTP was 8.8 months (95% CI 7.0 to 10.5) and median OS was 20.9 months (95% CI 17.7 to 24.1).

Conclusions The combination of SIRT and nivolumab has shown an acceptable safety profile and signs of antitumor activity in the treatment of patients with uHCC that were fit for SIRT.

Trial registration number NCT03380130

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Selective internal radiation therapy (SIRT) using yttrium-90 microspheres and PD1 inhibitors are used to treat patients with liver cancer but there is very limited information about the safety and efficacy of the combination of both therapies.

WHAT THIS STUDY ADDS

⇒ In patients with hepatocellular carcinoma (HCC) who are not good candidates for TACE despite being free from extrahepatic metastasis, SIRT using SIR-Spheres resin microspheres followed by nivolumab produced no new signs of enhanced toxicity, with most patients receiving nivolumab as planned, and the observed time to progression and overall survival were encouraging.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The efficacy of the combination of SIRT and nivolumab deserves to be studied in prospective randomized clinical trials in this population of patients with HCC and large or multiple tumors or those with segmental or lobar portal vein invasion. The outcomes observed in this study provide the benchmark for the design of such trials.

INTRODUCTION

Liver cancer is the third-leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) accounts for more than 80% of cases.1 Unresectable HCC patients are typically in the intermediate and advanced stages.2 Intermediate means asymptomatic, multinodular liver-only disease while advanced means mild impairment of performance status, vascular invasion or extrahepatic spread. Intraarterial therapies are the mainstay of the treatment of the former while systemic therapy is mostly used for the latter. Immunotherapy with the combination of atezolizumab plus bevacizumab is widely recommended as first-line systemic therapy for advanced HCC.3,4 Transarterial chemoembolization (TACE) is the most common...
inactivated. Nivolumab has demonstrated durable efficacy and preserved quality of life. Therefore, the combination of SIRT with an effective, well-tolerated systemic therapy could result in improved efficacy and preserved quality of life.

Nivolumab is a fully human immunoglobulin G4 that selectively blocks the interaction between programmed death 1 (PD-1) expressed on activated T cells, with its ligands PD-L1/PD-L2 thus preventing T cells from being inactivated. Nivolumab has demonstrated durable tumor responses with good tolerability in naïve and sorafenib-treated patients with advanced HCC. SIRT increases the presence of activated CD8+T cells in the tumor microenvironment and may therefore provide synergistic efficacy with Nivolumab. NASIR-HCC has assessed the combination of SIRT and immunotherapy in HCC patients with liver-only disease.

METHODS

Study design and population

NASIR-HCC (CA209-992) is a phase 2, multicenter, open-label, single-arm study of the safety and efficacy of Nivolumab in combination with SIRT using SIR-Spheres for the treatment of patients with HCC that are candidates for locoregional therapies. The study was conducted in nine academic centers in Spain (online supplemental file).

Eligible patients had unresectable HCC and were considered ineligible for TACE because either (i) they were in the BCLC-B2 substage, which includes single tumors (BCLC-A stage) if they are >5 cm or multiple tumors (BCLC-B stage) if they fall beyond the up-to-7 rule (number of tumors plus size of the largest lesion in cm >7); or (ii) they were in BCLC-C stage due to predominantly unilobar tumors with segmental or lobar PVI. Additional eligibility criteria are provided in online supplemental file.

All SIRT evaluations and treatments were centrally performed at Clinica Universidad de Navarra as a single-day procedure. A detailed SIRT protocol is provided in online supplemental file. SIRT was performed selectively, eventually through multiple microspheres injections, to preserve the largest possible liver volume from receiving any amount of radiation. Activity calculation took into account the cirrhotic status of the liver and the amount of liver volume spared from irradiation, with the aim to maximize tumor absorbed dose when deemed safe. Such individualized dosimetry was used whenever two liver segments were spared from radiation. Nivolumab (240 mg IV every 14 days) was started 3 weeks after SIRT visit and maintained until tumor progression, unacceptable toxicity or a maximum of 24 doses. Tumor response was assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 every 6 weeks for the first year, and then every 12 weeks thereafter until progression. Treatment with Nivolumab beyond progression was allowed under protocol-defined circumstances detailed in online supplemental file.

Outcomes

The primary endpoints were the rate and type of adverse events (AEs), serious AEs (SAEs), events of liver decompensation, and transient and permanent drug discontinuations due to toxicity. Immune-mediated adverse events (IMAE) related to nivolumab that were treated with corticosteroids were specifically recorded. Hepatic AEs (HAEs) were defined as those AE that have the liver as the target organ or represent usual complications of cirrhosis, including hepatobiliary events, liver-related investigations, thrombocytopenia, ascites, encephalopathy, spontaneous bacterial peritonitis and GI hemorrhage. Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE) V.4.0. Secondary endpoints are defined in detail in supplemental data and included overall response rate (ORR), disease control rate (DCR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), and pattern of progression. Exploratory objectives were overall survival (OS); efficacy based on tumor cell programmed death ligand 1 (PD-L1) expression and other tissue and blood biomarker; impact of the albumin-bilirubin (ALBI) score on safety and efficacy; and health related quality of life (HRQoL).

Statistical analyses

The primary objective was safety, but the study was considered key to explore the clinical benefit of combining nivolumab with SIRT. A sample size of 40 patients was determined adequate to provide safety information based on a 90% probability of observing at least one occurrence of any AE that might occur with a 5% incidence. At the time of study design, the estimated TTP after SIRT alone in a similar population was 3 months and sample size of 40 patients receiving SIRT plus at least 3 doses of Nivolumab would therefore allow to detect a relevant signal of incremental efficacy as detailed in online supplemental file.

Safety analysis included all patients who received SIRT while efficacy analysis included those who received SIRT and one or more doses of nivolumab. All AEs were...
summarized and reported by organ system, preferred term, and coded per the current version of the Medical Dictionary for Regulatory Activities. ORR and the corresponding 95% CI were calculated using the Clopper-Pearson method. The Kaplan-Meier method was used to analyze and plot time to events (TTP, DoR, PFS and OS) and median values were reported with 95% CI. The analysis of HRQoL will be reported separately.

RESULTS
Population and baseline characteristics
Forty-three patients were enrolled between January 2018 and April 2019 (figure 1). SIRT was contraindicated in one patient (2.3%) due to a hepatopulmonary shunt fraction >20%. The remaining 42 patients received SIRT and comprised the safety population. One patient with an incompetent ampulla of Vater developed liver abscesses after SIRT and never received Nivolumab, 27 discontinued Nivolumab during the study period mostly due to disease progression (n=17), and 14 patients received 24 doses of nivolumab as planned. Baseline demographic and clinical characteristics are listed in table 1. Six patients had received sorafenib, with a median of 10 weeks between the last dose of sorafenib and study entry.

Treatment
SIRT details are summarized in online supplemental table S1. The median time from informed consent to SIRT was 22 days (IQR 12 days). An effort was made to perform SIRT highly selectively. According to the volume of liver receiving any amount of radiation, SIRT was sublobar in 17%, lobar in 55%, and extended lobar or whole-liver in 28%, with multiple SIR-Spheres injections performed in 62% of patients. Activity was calculated using the partition model to maximize the dose delivered to the tumor compartment at >120 Gy in 25 patients (tumor-targeted dose group) while in the remaining 17 patients (liver-targeted dose group) either the partition model was used to restrict the dose delivered to the non-tumoral compartment to 40 Gy (n=9) or a modified BSA method was used to calculate the activity (n=8).

At database lock in February 2021, the median minimum follow-up was 22.2 months (range 2.7–35.6). The median time from SIRT to first dose of nivolumab was 3.1 weeks and 3 patients started nivolumab 4 weeks or more after SIRT (4.5, 4.8, and 6.1 weeks) due to AEs. Twenty-eight patients (66.6%) discontinued or never received nivolumab. The reason for treatment discontinuation was as per investigator’s decision in 4 patients. In three of these cases tumors previously considered unresectable turned resectable after tumor regression and/or contralateral hypertrophy. One additional patient who interrupted nivolumab due to diarrhea was also considered resectable. Complete tumor resection was achieved in these 4 patients 26, 27, 37, and 46 weeks after SIRT, with no postoperative deaths recorded. All four patients were alive and recurrence-free 11, 16, 17 and 29 months after resection (22, 23, 24 and 35 months after SIRT). Patients were on nivolumab for a median of 32.9 weeks (range 2.1–48.8 weeks). Fourteen patients (33.3%) completed nivolumab treatment as planned. Seven patients who reached the end of the treatment period with stable disease (n=4) or showing partial tumor response (n=3) were maintained on Nivolumab off-study based on local availability and investigator decision. Nine patients (21.9%) received tyrosine kinase inhibitors poststudy.

Safety
A summary of AEs is presented in table 2. AEs and SAEs grade 3–4 were observed in 19% and 26% of patients,
respectively. No treatment-related deaths were reported. The incidence and type of SAEs was not different in patients in the BCLC-B2 substage versus those with lobar PVI. Treatment-related AE related to nivolumab (IMAE) or SIRT are detailed in table 3.

Eighteen patients (43.9%) had at least one nivolumab dose delay due to AEs (online supplemental table S2) and three patients (7.2%) had three or more dose delays. HAEs resulted in dose delays in 9 (21.4%) patients. Delays occurred less frequently after sublobar SIRT (14.2%) compared with lobar (52.1%) or lobar extended/whole-liver SIRT (25%). Nivolumab was discontinued due to AEs in six patients (online supplemental table S3). Two such AEs were considered related to SIRT (liver abscesses in a patient with incompetent ampulla of Vater despite antibiotic prophylaxis; and hyperbilirubinemia) and one

Table 1  Patient demographics and baseline characteristics

|                              | All patients | BCLC-B2 substage | Unilobar tumors with portal vein invasion |
|------------------------------|--------------|------------------|------------------------------------------|
| Patients (n, %)              | 42 (100)     | 31 (73.8)        | 11 (26.2)                                |
| Males (n, %)                 | 36 (85.7)    | 27 (87.1)        | 9 (81.1)                                 |
| Age in years (median, IQR)   | 65 (49–79)   | 65 (49–79)       | 65 (55–79)                               |
| Vascular invasion (n, %)     | 11 (26.2)    | 0                | 11 (100)                                 |
| BCLC stage (n, %)            |              |                  |                                          |
| A                            | 3 (7.1)      | 3 (9.7)          | 0                                        |
| B                            | 25 (59.6)    | 25 (80.6)        | 0                                        |
| C                            | 14 (33.3)    | 3 (9.7)          | 11 (100)                                 |
| Etiology (n, %)              |              |                  |                                          |
| Uninfected                   | 32 (76.2)    | 25 (80.6)        | 7 (63.6)                                 |
| Hepatitis C                  | 9 (21.4)     | 5 (16.1)         | 4 (36.4)                                 |
| Hepatitis B                  | 1 (2.4)      | 1 (3.2)          | 0                                        |
| Alcohol consumption (n, %)   | 5 (11.9)     | 3 (9.6)          | 2 (18.1)                                 |
| Arterial hypertension (n, %) | 20 (47.6)    | 16 (51.6)        | 4 (36.4)                                 |
| Diabetes (n, %)              | 10 (23.8)    | 7 (22.6)         | 3 (27.3)                                 |
| Dyslipidemia (n, %)          | 9 (21.4)     | 8 (25.8)         | 1 (9.1)                                  |
| ECOG performance status (n, %)|            |                  |                                          |
| 0                            | 38 (90.5)    | 28 (90.3)        | 10 (90.9)                                |
| 1                            | 4 (9.5)      | 3 (9.7)          | 1 (9.1)                                  |
| Child-Pugh class (n, %)      |              |                  |                                          |
| A5                           | 36 (85.7)    | 27 (87.1)        | 9 (81.8)                                 |
| A6                           | 6 (14.3)     | 4 (12.9)         | 2 (18.2)                                 |
| ALBI grade (n, %)            |              |                  |                                          |
| 1                            | 21 (50)      | 17 (54.9)        | 4 (36.4)                                 |
| 2                            | 21 (50)      | 14 (45.1)        | 7 (63.6)                                 |
| Previous treatment (n, %)    |              |                  |                                          |
| Liver resection              | 7 (16.7)     | 5 (16.1)         | 2 (18.2)                                 |
| Percutaneous ablation        | 6 (14.3)     | 5 (16.1)         | 1 (9.1)                                  |
| TACE                         | 11 (26.2)    | 11 (35.5)        | 0                                        |
| Sorafenib                    | 6 (14.3)     | 5 (16.1)         | 1 (9.1)                                  |
| Alpha-fetoprotein >400 ng/mL (n, %) | 12 (29.3) | 7 (23.3) | 5 (45.5) |
| Platelet count, /pL (median, IQR) | 141 (46–512) | 139 (46–512) | 145 (59–288) |
| Total bilirubin, mg/dL (median, IQR) | 0.76 (0.20–1.89) | 0.72 (0.20–1.89) | 0.90 (0.40–1.40) |
| Albumin, g/dL (median, IQR)  | 3.95 (3.00–4.80) | 4.00 (3.00–4.80) | 3.83 (3.20–4.80) |
| Neutrophil to lymphocyte ratio (median, IQR) | 2.69 (1.86–4.25) | 2.61 (1.83–4.15) | 3.38 (1.87–4.34) |

ALBI, Albumin-Bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; TACE, Transarterial chemoembolization.
was related to nivolumab (grade 3 diarrhea). Events of liver decompensation occurred in 18 (42.9%) patients during follow-up and were more frequent among patients receiving a liver-targeted dose (n=11, 61.1%) than a tumor-targeted dose (n=7, 38.9%), and correspondingly among patients receiving SIRT with a whole-liver or lobar extended design (n=8, 44.4%) vs a sublobar design (n=4, 16.6%).

Nine IMAEs requiring steroids were reported in eight patients and are listed in online supplemental table S4. One patient permanently discontinued Nivolumab due to diarrhea while the other patients with IMAEs were able to resume it. No patient required treatment with immunosuppressors other than corticosteroids.

HAEs that (A) were grade 3 or 4, (B) resulted in nivolumab dose delays or discontinuation, (C) were related to SIRT or to nivolumab, or (D) consisted in increased bilirubin or complications of cirrhosis, were observed more frequently in patients receiving SIRT with a whole-liver or lobar extended design (n=8, 44.4%) vs a sublobar design (n=4, 16.6%).

Nine IMAEs requiring steroids were reported in eight patients and are listed in online supplemental table S4. One patient permanently discontinued Nivolumab due to diarrhea while the other patients with IMAEs were able to resume it. No patient required treatment with immunosuppressors other than corticosteroids.

HAEs that (A) were grade 3 or 4, (B) resulted in nivolumab dose delays or discontinuation, (C) were related to SIRT or to nivolumab, or (D) consisted in increased bilirubin or complications of cirrhosis, were observed more frequently in patients with ALBI grade 2 at baseline (table 4). As the volume of SIRT-targeted liver increased from sublobar to lobar or whole-liver SIRT, the proportion of patients with HAEs related to SIRT also increased, but the incidence of HAEs resulting in nivolumab dose delays or discontinuation was similar between subgroups. When treatment-related AEs of any class resulting in nivolumab dose delays were considered (and not only HAEs), a similar proportion of patients had baseline ALBI grades 1 and 2 (62% and 47%, respectively).

### Table 2  Summary of AEs

| Patients with adverse events, no (%)* | Any grade | Grade 3–4 |
|--------------------------------------|-----------|-----------|
| All causality AEs                    | 41 (98)   | 8 (19)    |
| Treatment-related AEs                | 33 (79)   | 8 (19)    |
| Related to SIRT                      | 21 (50)   | 2 (5)     |
| Related to nivolumab (IMAE)          | 27 (64)   | 6 (14)    |
| All causality SAEs                   | 21 (50)   | 11 (26)   |
| Treatment-related SAEs               | 5 (12)    | 5 (12)    |
| Related to SIRT                      | 1 (2)     | 1 (2)     |
| Related to Nivolumab (IMAE)          | 4 (9)     | 4 (9)     |

AEs of special interest with incidence >10%

- Hepatic: 30 (71) 8 (19)
- Blood: 16 (38) 0
- Gastrointestinal: 16 (38) 3 (7)
- Skin: 12 (29) 0
- Endocrine: 10 (24) 2 (5)

*AEs and SAEs are reported separately.

AE, adverse event; SAEs, serious AEs; SIRT, selective internal radiation therapy.

### Table 3  Treatment-related adverse events related to SIRT or nivolumab

| System organ class, preferred term | Patients with treatment-related adverse events, no (%) |
|-----------------------------------|------------------------------------------------------|
| Event                             | Any grade | Grade 3–5 |
| Related to SIRT                   |           |           |
| Hepatobiliary disorders           |           |           |
| Hyperbilirubinemia                | 8 (19)    | 1 (2)     |
| ALT increased                     | 1 (2)     | 0         |
| AST Increased                     | 1 (2)     | 0         |
| Blood and lymphatic system disorders |         |           |
| Thrombocytopenia                  | 7 (17)    | 0         |
| Lymphopenia                       | 1 (2)     | 0         |
| Infections and infestations       |           |           |
| Liver abscess                     | 1 (2)     | 1 (2)     |
| Gastrointestinal disorders        |           |           |
| Ascites                           | 1 (2)     | 0         |
| General disorders                 |           |           |
| Fever                             | 1 (2)     | 0         |
| Vascular disorders                |           |           |
| Hematoma                          | 1 (2)     | 0         |
| Related to nivolumab (IMAEs)      |           |           |
| Hepatobiliary disorders           |           |           |
| ALT increased                     | 5 (12)    | 1 (2)     |
| AST increased                     | 6 (14)    | 1 (2)     |
| Hyperbilirubinemia                | 2 (5)     | 0         |
| Immune hepatitis                  | 2 (5)     | 1 (2)     |
| Endocrine disorders               |           |           |
| Hypothyroidism                    | 4 (10)    | 0         |
| Thyroiditis                       | 2 (5)     | 0         |
| Hyperthyroidism                   | 1 (2)     | 0         |
| Skin and subcutaneous tissue disorders |         |           |
| Pruritus                          | 4 (10)    | 0         |
| Rash                              | 3 (7)     | 0         |
| Dermatitis                        | 2 (5)     | 0         |
| Gastrointestinal disorders        |           |           |
| Diarrhea                          | 2 (5)     | 1 (2)     |
| Blood and lymphatic system disorders |       |           |
| Anemia                            | 2 (5)     |           |
| Metabolism and nutrition disorders |       |           |
| Diabetes mellitus                 | 1 (2)     | 1 (2)     |
| Hyperosmolar nonketotic syndrome  | 1 (2)     | 1 (2)     |
| Renal and urinary disorders       |           |           |
| Renal impairment                  | 1 (2)     | 1 (2)     |
| Tubulointerstitial nephritis      | 1 (2)     | 1 (2)     |

Continued
Efficacy
As per investigator assessment, complete and partial responses were observed in 5 and 12 patients, respectively, accounting for an ORR of 41.5% (95% CI 26.3% to 57.9%). Stable disease was the best overall response in 21 patients accounting for a DCR of 92.7% (95% CI 80.1% to 98.5%). No patient or tumor baseline characteristic, including prior TACE or Sorafenib, was associated with relevant differences in ORR, although responses were more frequent when Y90 activity was calculated based on a tumor-targeted dose (online supplemental table S5). Median time to response was 9 weeks (range 1–50 weeks) and median DoR was 31 weeks (range 6–109 weeks). Eleven (26.8%) patients had ongoing responses at the time of analysis. The waterfall plot of changes in target lesions is shown in online supplemental figure S1.

During the follow-up, 28 patients experienced disease progression, and 27 patients died. First progression was in form of growth of pre-existing lesions in 9 patients, new intrahepatic lesions in 10, and new extrahepatic lesions in 9. Median TTP was 8.8 months (95% CI 7.0 to 10.5) (figure 2). There was tendency to a shorter TTP among patients with vascular invasion, alpha-fetoprotein (AFP)>400 ng/mL or liver-targeted dose that was statistically significant only for AFP >400 ng/mL (online supplemental table S6 and figures S2–S4). Median PFS was 9.0 months (95% CI 7.0 to 10.9) (online supplemental figure S5).

Median OS was 20.9 months (95% CI 17.7 to 24.1) (figure 3). A trend was observed toward shorter OS among patients with AFP >400 ng/mL or liver-targeted dose that was significant for the former (online supplemental table S6 and figure S6 and S7).

DISCUSSION
To our knowledge, this is the first full report of a prospective evaluation of the combination of SIRT and nivolumab in a cohort of patients with HCC free from extrahepatic metastasis. The combination showed a tolerable safety profile with no signs of synergistic toxicity, and promising ORR, TTP, and OS. SIRT has shown a favorable safety profile and antitumor activity in retrospective and prospective cohorts of patients with intermediate through advanced stage HCC including those with too many or too large tumors, a wide range of patterns of PVI, or in progression to TACE. A recent publication has described the effects of this same combination in a more heterogenous and advanced group of HCC patients including a substantial number of patients with extrahepatic disease. Indeed, authors concluded that the strategy should be further evaluated in patients with HCC ineligible for TACE and patients with advanced stage but without extrahepatic spread. In NASIR-HCC, we established such stringent patient selection criteria to help define the safety and potential efficacy of SIRT and nivolumab in a homogeneous population that could be the target for future controlled clinical trials, excluding those patients with limited tumor burden where SIRT would be a radical therapy, and also those with extrahepatic metastasis where a locoregional therapy will unlikely have any benefit. The similar safety profile and OS in the two subgroups of patients in the BCLC-B2 substage and limited PVI supports our choice as a reasonable target population.

Nivolumab has demonstrated a good safety profile and relevant activity in patients that were mostly in the advanced stage. Yet, when tested against sorafenib as first-line therapy in advanced HCC a superior OS was not shown. The safety of the combination with SIRT was acceptable and there were no signs of new or synergistic liver or lung toxicity, the main organs with overlapping AEs. This is in line with the finding that administration of an ICI within 90 days following external irradiation was not associated with an increased risk of SAEs. The most frequent AEs were those expected from SIRT (thrombocytopenia, asthenia, and increased bilirubin) or nivolumab (diarrhea, asthenia, increased transaminases, or pruritus). SIRT-related AEs caused nivolumab discontinuation in only two patients. Patients with worse liver functional reserve in ALBI grade 2 at baseline had higher rates of HAEs but not AEs of any class resulting in Nivolumab delays or discontinuation.

Regarding efficacy, data from prospective trials using SIRT in HCC can provide a reasonable perspective to assess the outcomes observed in this trial. Reported median PFS and OS in trials including patients considered unsuitable for TACE were 4.1 and 8.0 months, respectively, in the SARAH trial, and 5.8 and 8.8 months SIRVENIB trial. In randomized trials comparing SIRT versus TACE among patients suited for TACE, median PFS and OS ranged from 3.6 and <12 months in the SIRTACE trial to 6 and 19.7 months in a German trial. Median PFS at 9 months and median OS at 20.9 months in NASIR-HCC are consistently higher and suggest enhanced activity of the combination of SIRT with nivolumab. When considering only the BCLC-B2 substage, again the 10.6 months median PFS observed in this trial compares well with the 6.2 months reported in a multicenter retrospective series of SIRT-treated patients. Response to SIRT is usually delayed for several months and the median time to

---

### Table 3

| Event | Any grade | Grade 3-5 |
|-------|-----------|-----------|
| Blood creatinine increased | 1 (2) | 0 |
| Musculoskeletal and connective tissue disorders | | |
| Back pain | 1 (2) | 0 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; SIRT, selective internal radiation therapy.
Table 4  Patients with hepatic adverse events of all causality, including hepatobiliary events, liver-related investigations, liver-related infections, thrombocytopenia, ascites, encephalopathy, bacterial peritonitis and GI hemorrhage

| All patients (n=42) | 1 (n=21) | 2 (n=21) | SIRT design | Tumor burden |
|---------------------|----------|----------|-------------|--------------|
|                     | n  | %  | n  | %  | n  | %  | n  | %  | n  | %  | n  | %  | n  | %  |
| Any grade           |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Grade 3–4           |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Resulting in nivolumab dose delay |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Related to SIRT     |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Related to nivolumab|    |    |    |    |    |    |    |    |    |    |    |    |    |
| Type of event       |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Any grade           | 32 | 76.2 | 16 | 76.2 | 16 | 76.2 | 5 | 71.4 | 15 | 65.2 | 12 | 100.0 | 25 | 80.6 | 7 | 63.6 |
| Grade 3–4           | 9  | 21.4 | 2  | 9.5  | 7  | 33.3 | 2 | 28.6 | 4  | 17.4 | 3  | 25.0  | 7  | 22.6 | 2 | 18.2 |
| Resulting in nivolumab dose delay | 11 | 26.2 | 1 | 4.8  | 10 | 47.6 | 2 | 28.6 | 5  | 36.7 | 2  | 28.6  | 2  | 22.6 | 3 | 18.2 |
| Related to SIRT     | 14 | 33.3 | 6  | 28.6 | 8  | 38.1 | 1 | 14.3 | 6  | 26.1 | 7  | 33.3  | 13 | 34.1 | 1 | 9.1 |
| Related to nivolumab| 7  | 16.7 | 2  | 9.5  | 5  | 23.8 | 1 | 14.3 | 3  | 13.0 | 3  | 25.0  | 6  | 19.4 | 1 | 9.1 |

Table continued...

- *Includes events of ‘increased AST’, ‘increased ALT’ or ‘hypertransaminasemia’.
- †Includes events of ‘increased bilirubin’ or ‘hyperbilirubinemia’.

ALBI, Albumin-Bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; GGT, Gamma-glutamyl transpeptidase; GI, gastrointestinal; PVI, portal vein invasion; SIRT, selective internal radiation therapy.
response of 9 weeks observed in this study is certainly shorter than what would be expected from SIRT alone. The high DCR at 93% was strongly influenced by the first evaluation of tumor response 3 weeks after SIRT, an early time point when most tumors are expected to remain stable.

Several studies have demonstrated that delivering a high dose of radiation to the tumor compartment is key to obtain a good long-term outcome after SIRT. The data from NASIR-HCC point in the same direction and highlight the importance of treatment design and activity calculation in maximizing the effectiveness of SIRT.

Limitations
The single-arm design of the study should prompt caution in the interpretation of results compared with other prospective and retrospective cohorts, in particular with those large randomized trials that included patients in more advanced stages like SARAH, SIRveNIB and SORAMIC. Performing all SIRT procedures in a single center minimizes the effect of different levels of expertise across centers but may impact the reproducibility of the results.

Conclusions
The NASIR-HCC trial has shown that the combination of SIRT with SIR-Spheres resin microspheres, followed by nivolumab was safe and active as first-line therapy of patients with locally advanced HCC ineligible for TACE, where SIRT alone has failed to prove superiority over the standard of care. The high DCR, prolonged TTP, and encouraging OS suggest that the combination could be an option for this population and should be tested in a phase 3 controlled trial.

Immune checkpoint inhibitors in combination with other therapies may provide a clinical benefit for advanced HCC patients naïve to systemic therapy. Atezolizumab plus bevacizumab has become a standard of care after proving superior OS and PFS compared with sorafenib. Improved OS and PFS benefits with the anti-PD-1 Sintilimab plus a Bevacizumab biosimilar was also shown in HBV-associated HCC. More recently, tremelimumab plus durvalumab has shown superior OS and PFS versus sorafenib. However, combinations come with more strict inclusion criteria compared with anti-PD-1/PD-L1 monotherapies, particularly for patients with cardiovascular comorbidities. SIRT plus nivolumab could be a valuable alternative for this subgroup of patients lacking an evidence-based recommended therapy.
Contributors BS and MdIT-A are responsible for the overall content as guarantors and as such they accept full responsibility for the finished work and the conduct of the study, had access to the data, and controlled the decision to publish. Concept and design: MdIT-A, JIB, BS. Acquisition, analysis or interpretation of data: MdIT-A, AM, MV, MI, MR, JLL, JIA, SL, MT, LM, LDF, JIA, CG-M, MR-F, JIB and BS. Drafting of manuscript: MdIT-A, AM, MV, MI, MR, JLL, JIA, SL, MT, LM, LDF, JIA, CG-M, MR-F, JIB and BS. Critical revision of the manuscript for important intellectual content: MdIT-A, AM, AV, MI, MR, JLL, JIA, SL, MT, LM, LDF, JIA, CG-M, MR-F, JIB and BS. Statistical analysis: MdIT-A and BS.

Funding This study was supported by Bristol Myers Squibb (Princeton, New Jersey, USA) and Sirtex Medical (Woburn, Massachusetts, USA).

Disclaimer The funding organizations did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or approval of the manuscript; and decision to submit the manuscript for publication. They have provided comments to the final draft.

Competing interests MdIT-A: travel grants from EISAI, Bayer and Pfizer. AM: consultancy fees from Astra-Zeneca, Bayer, Eisai-MSD, Roche and Sirtex Medical; and travel expenses from Astra-Zeneca, Bayer and Boston Scientific. MV: consultancy fees from Astra-Zeneca, Bayer, BM, Roche and Sirtex Medical; and honoraria from Bayer, Boston, Gilead, Eisai-MSD and Abbvie; and travel expenses from Astra-Zeneca and Bayer. MI: lecture fees and travel support from BM; MR: consultancy fees from Astra-Zeneca, Bayer, BM, Boston Science, Ipsen, Lilly and Roche; lecture fees from Bayer, BM, Gilead, Lilly, Roche and UniversalkD; travel support from Astra-Zeneca, Bayer, BM, Sirtex Medical; research funding (to institution) from Bayer and Ipsen. JLL: speaker fees from Bayer and Eisai-MSD; consultancy fees from Bayer, Eisai-MSD and Roche. JIA: none. JIB: travel fees from BMS and Sirtex Medical. AB: consultancy fees from Astra-Zeneca, BMS, Abbvie and Roche; advisory fees from BMS, Ipsen and Roche; MI: advisory fees from Anagenesis, Astra-Zeneca, BMS, Eisai, Hengrui Therapeutics, MerckX and Roche-Spain; speaker fees from Eisai and Eli-Lilly. MR-F: consultancy and speaker fees from Sirtex Medical. BS: consultancy fees from Boston Scientific, MSD, Sirtex Medical and Terumo; speaker fees from Sirtex; research grants from Sirtex and Terumo. CG-M: consultancy fees from Adaptimmune, Astra Zeneca, Bayer, BM, Boston Scientific, BTG, Eisai, Eli Lilly, H3 Biomedicine, Ipsen, Novartis, Merck, Roche, Sirtex Medical and Terumo; speaker fees from Astra Zeneca, Bayer, BM, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical and Terumo; research grants (to Institution) from BM and Sirtex Medical.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval The study protocol was approved by the ethics committee (Comité Ético de Investigación Clínica de Navarra, EudractID, 2017-000232-01, internal code 20/17) and the study was done in accordance with Good Clinical Practice guidelines. All patients provided written informed consent before study participation based on the principles of the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any errors and/or omissions arising from translation or adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Manuel de la Torre-Aláez http://orcid.org/0000-0002-1972-3933
Macarena Rodríguez-Fraile http://orcid.org/0000-0002-9069-7918

REFERENCES
1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2 Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76:681–93.
3 Bruix J, Chen SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 2021;75:S60–74.
4 Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv238–55.
5 Sangro B, iñarrairaegui M, Bilbao JL. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464–73.
6 Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868–78.
7 Vilgrain V, Peterea H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624–36.
8 Chow PKH, Gandhi M, Tan S-B, et al. SIRVeNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with advanced hepatocellular carcinoma. J Clin Oncol 2018;36:1913–21.
9 Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019;71:1164–74.
10 de la Torre-Aláez M, Jordan-İbora C, Casadei-Gaardøn A, et al. The patterns of progression define post-progression survival in patients with hepatocellular carcinoma treated with SIRT. Cardiovasc Intervent Radiol 2020;43:1165–72.
11 Sangro B, Sarobe P, Hervás-Stubbbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:552–63.
12 El-Khoueiry AB, Sangro B, Yao T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–502.
13 Sangro B, Park J, Finn R, et al. LBA-3 CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Ann Oncol 2020;31:S241–2.
14 Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019;68:335–46.
15 Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Sermín Liver Dis 2012;32:348–59.
16 Gil-Álzagaray B, Chopitea A, iñarrairaegui M, et al. Prognostic factors and prevention of radioembolisation-induced liver disease. Hepatology 2013;57:1078–87.
17 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
18 Kolligs FT, Bilbao JL, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015;35:1715–21.
19 Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018;68:1429–40.
20 Garin E, Tsilika L, Guï B, et al. Personaliised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17–29.
21 Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (Ca 209-878): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:1025–35.
22 Fessas P, Kaseb A, Wang Y, et al. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 2020;8:e001033.
23 Yao T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III trial of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (PTS) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v874–5.
24 Anscher MS, Arora S, Weinstock C, et al. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US food and drug administration database. *JAMA Oncol* 2022;8:232–40.

25 Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol* 2017;18:1624–36.

26 Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 2015;38:352–60.

27 Cappelli A, Sangro P, Mosconi C, et al. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. *Eur J Nucl Med Mol Imaging* 2019;46:661–8.

28 Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. *Int J Radiat Oncol Biol Phys* 2011;79:163–71.

29 Hermann A-L, Dieudonné A, Ronot M, et al. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study. *Radiology* 2020;296:673–84.

30 Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med Overseas Ed* 2020;382:1894–905.

31 Ren Z, Fan J, Xu J, et al. LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32). *Ann Oncol* 2020;31:S1287.

32 Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (PTS) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. *JCO* 2022;40:379.

33 Ricke J, Klümpen HJ, Arthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. *J Hepatol* 2019;71:1164–74.